Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020
October 26, 2020 at 04:55 am EDT
Share
Wuhan Hiteck Biological Pharma Co.,Ltd announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was CNY 348.594 million compared to CNY 470.523 million a year ago. Operating loss was CNY 8.902 million compared to operating Income of CNY 83.780 million a year ago. Net loss was CNY 10.526 million compared to net income of CNY 68.128 million a year ago. Basic loss per share from continuing operations was CNY 0.1 compared to basic earnings per share from continuing operations of CNY 0.66 a year ago.
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical company. The Company operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segmentâs businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.
WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD 
